T. Rowe Price Associates
VNDA icon

T. Rowe Price Associates’s Vanda Pharmaceuticals VNDA Stock Holding History

T. Rowe Price Associates’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$289K Buy
41,820
+6,537
+19% +$50.4K ﹤0.01% 2699
2025
Q4 		$312K Buy
35,283
+6,027
+21% +$33.2K ﹤0.01% 2626
2025
Q3 		$146K Buy
29,256
+2,491
+9% +$11.5K ﹤0.01% 2860
2025
Q2 		$127K Hold
26,765
– – ﹤0.01% 2847
2025
Q1 		$123K Buy
26,765
+4,500
+20% +$21K ﹤0.01% 2782
2024
Q4 		$107K Buy
22,265
+3,370
+18% +$16.2K ﹤0.01% 2823
2024
Q3 		$89K Buy
18,895
+1,865
+11% +$10K ﹤0.01% 2843
2024
Q2 		$97K Buy
17,030
+1,206
+8% +$6.23K ﹤0.01% 2764
2024
Q1 		$66K Buy
15,824
+2,425
+18% +$9.71K ﹤0.01% 2837
2023
Q4 		$57K Buy
13,399
+1,244
+10% +$5.02K ﹤0.01% 2791
2023
Q3 		$53K Buy
12,155
+726
+6% +$4.03K ﹤0.01% 2771
2023
Q2 		$76K Buy
11,429
+1,049
+10% +$6.72K ﹤0.01% 2740
2023
Q1 		$71K Buy
+10,380
New +$73K ﹤0.01% 2742
2015
Q2 		– Sell
-365,628
Closed -$3.4M – 2560
2015
Q1 		$3.4M Sell
365,628
-4,209,593
-92% -$47.6M ﹤0.01% 1524
2014
Q4 		$65.5M Buy
4,575,221
+470,700
+11% +$5.57M 0.01% 744
2014
Q3 		$42.6M Buy
4,104,521
+677,730
+20% +$8.88M 0.01% 889
2014
Q2 		$55.4M Buy
3,426,791
+1,674,910
+96% +$22.3M 0.01% 831
2014
Q1 		$28.5M Buy
1,751,881
+543,480
+45% +$7.73M 0.01% 1017
2013
Q4 		$15M Buy
1,208,401
+1,185,201
+5,109% +$11.9M ﹤0.01% 1175
2013
Q3 		$255K Sell
23,200
-5,100
-18% -$54.5K ﹤0.01% 2174
2013
Q2 		$229K Buy
+28,300
New +$191K ﹤0.01% 2165

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's VNDA Position: Q1 2026 in Review

T. Rowe Price Associates increased its Vanda Pharmaceuticals (VNDA) stake by 19% in Q1 2026, buying an estimated $50.4K and bringing the position to 41,820 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #2699.

T. Rowe Price Associates first reported a position in VNDA in Q2 2013 and has held it in 21 quarters since. The position peaked at $65.5M in Q4 2014. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • T. Rowe Price Associates held 41,820 shares of Vanda Pharmaceuticals worth $289K as of Q1 2026.
  • T. Rowe Price Associates bought 6,537 Vanda Pharmaceuticals shares in Q1 2026, an estimated $50.4K.
  • Vanda Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2699 holding.
  • T. Rowe Price Associates first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 21 quarters since.
  • T. Rowe Price Associates's Vanda Pharmaceuticals position peaked at $65.5M in Q4 2014.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.